Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Total Review Period for Standard Products Reduced by 4.5 Months to 14.7 Months: PMDA
July 18, 2011
- Positive PII Results for Takeda's TAK-875 Presented at ADA
July 18, 2011
- Ryukaikon Calls For Further Studies on Bar Code Labeling
July 18, 2011
- Committee Starts Discussing Relief System for Victims of Health Hazards Caused by Anticancer Drugs
July 18, 2011
- Positive Results for Central Neuropathic Pain with Lyrica in PIII Trial: Pfizer
July 18, 2011
- SymBio Licenses Rigosertib from Onconova for MDS
July 18, 2011
- Takeda Recalls Actos, Competact in France
July 18, 2011
- Combined with Insulin, Lixisenatide Decreases HbA1c
July 18, 2011
- Hisamitsu to Launch Norspan Tape in Early August Aiming for ¥1.3 Bil. Sales in FY2011
July 18, 2011
- Senju Files for Glaucoma Treatment Seen as Next-generation Strategic Product
July 18, 2011
- Eisai to Accelerate Biomarker Research with Its Subsidiary EIDIA
July 18, 2011
- Roche Returns Overseas Development, Marketing Rights for SGLT-2 Inhibitor to Chugai
July 18, 2011
- Pancreatic Cancer Approved as Add'l Indication for Tarceva: Chugai
July 18, 2011
- DPC Subcommittee to Look at Fixed-sum Reimbursement per Hospitalization for High-priced Drugs
July 18, 2011
- Further Consolidation of Dispensing Pharmacies Expected: Mr Ubunuki of Yano Research
July 18, 2011
- GSK Obtains Marketing Approval for Rotarix
July 18, 2011
- Taisei Kako Co-develops New Prefilled Syringe with Suzuken
July 18, 2011
- Kyowa Kirin to Enforce Safe Driver Education for New MRs
July 18, 2011
- 3 Products Including 4-Valent HPV Vaccine Gardasil Approved: MSD
July 18, 2011
- Nippon Kayaku Takes over Manufacturing Approval for Gelpart from Astellas
July 18, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…